|
|
Article: Somaxon Pharmaceuticals Announces Positive Phase 3 Results with SILENOR(TM) for the Treatment of Adults with Chronic Insomnia.
- Article from:
- PR Newswire
- Article date:
- April 10, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- SILENOR(TM) demonstrated statistically significant improvements in the primary endpoint: Wake After Sleep Onset
- Significant improvements were also demonstrated in key secondary endpoints, including Latency to Persistent Sleep, Total Sleep Time, and Sleep Efficiency
SAN DIEGO, April 10 /PRNewswire-FirstCall/ -- Somaxon Pharmaceuticals, Inc. , today announced positive results from its initial Phase 3 clinical trial with the tested doses of 3 mg and 6 mg of SILENOR(TM) (doxepin HCl), achieving statistically significant results in adults with chronic insomnia. Results of the primary endpoint for this trial, 8-hour Wake After Sleep Onset (WASO), which ...